Oral-M®證實可區分口腔扁平苔蘚與上皮細胞變異
日祥最新研究發表顯示Oral-M® 可區分口腔扁平苔蘚(OLP)與上皮細胞變異之口腔癌前病變和口腔鱗狀細胞癌
日祥於近期在Oral Diseases期刊發表多中心臨床研究之最新結果。此研究在中山醫學大學附設醫院(CSMUH)、馬偕紀念醫院(MMH)和台北榮民總醫院(TVGH)進行，證實Oral-M® (ZNF582甲基化檢測)可區分口腔扁平苔蘚(OLP)以及上皮細胞變異和口腔鱗狀細胞癌(OSCC)。
本研究納入220位具菸檳習慣或自覺口腔黏膜有異常症狀的患者，分成上皮細胞變異、OSCC、OLP以及正常組之4個組別。結果顯示OLP組(含病灶處和其鄰近正常部位)之ZNF582甲基化程度與正常組相近；OLP組之ZNF582甲基化程度則低於上皮細胞變異和OSCC兩組。研究亦指出，在上皮細胞變異/OSCC組中，具有嚼食檳榔和抽菸之高風險生活習慣的患者，其ZNF582甲基化明顯高於沒有菸檳行為生活習慣的患者。而OLP患者其ZNF582甲基化程度則不受高風險生活習慣影響。
透過ZNF582甲基化程度證明OLP潛在惡性之可能性較低。
因此在臨床應用上Oral-M®可用以區分OLP與真正上皮細胞變異和口腔鱗狀細胞癌。
|
|
New publication shows that Oral-M® can distinguish oral lichen planus from other oral potentially malignant disorder with true dysplastic features and OSCC |
 |
New Taipei City, January 28, 2022. iStat Biomedical Co., Ltd. (iStat Co.), shows data from multicenter trial were published in Oral Diseasesa.
This new study conducted in Chung Shan Medical University Hospital (CSMUH), Mackay Memorial Hospital (MMH) and Taipei Veterans General Hospital (TVGH), demonstrates that Oral-M® (ZNF582 methylation test) is able to distinguish oral lichen planus (OLP) from dysplasias and oral squamous cell carcinomas (OSCC).
This study has recruited 220 patients who were self-aware of oral abnormalities with 42 and 90 biopsy-confirmed dysplasias and OSCC patients, 43 clinically diagnosed OLP patients, and 45 normal controls. OLP lesions as well as adjacent normal showed comparable low ZNF582 methylation to normal control group, and lower than those of dysplasia and OSCC. Study also showed that dysplasia/OSCC patients with high-risk habits exhibited significantly higher ZNF582 methylation than those without high-risk habits. However, OLP patients were not affected by high-risk habits.
Based on ZNF582 methylation levels, OLP is unlikely to be potentially malignant. These clinical performance data support the use of Oral-M® for distinguishing OLP from true dysplastic features and OSCC during the clinical practice.
- Chiu, Y.-W., Su, Y.-F., Yang, C.-C., Liu, C.-J., Chen, Y.-J., Cheng, H.-C., Wu, C.-H., Chen, P.-Y., Lee, Y.-H., Chen, Y.-L., Chen, Y.-T., Peng, C.-Y., Lu, M.-Y., Yu, C.-H., Kao, S.-Y., Fwu, C.-W., & Huang, Y.-F. (2022). Is OLP potentially malignant? A clue from ZNF582 methylation. Oral Diseases, 00, 1–9. https://doi.org/10.1111/odi.14120
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518
日祥最新研究發表顯示Oral-M® 可區分口腔扁平苔蘚(OLP)與上皮細胞變異之口腔癌前病變和口腔鱗狀細胞癌
日祥於近期在Oral Diseases期刊發表多中心臨床研究之最新結果。此研究在中山醫學大學附設醫院(CSMUH)、馬偕紀念醫院(MMH)和台北榮民總醫院(TVGH)進行，證實Oral-M® (ZNF582甲基化檢測)可區分口腔扁平苔蘚(OLP)以及上皮細胞變異和口腔鱗狀細胞癌(OSCC)。
本研究納入220位具菸檳習慣或自覺口腔黏膜有異常症狀的患者，分成上皮細胞變異、OSCC、OLP以及正常組之4個組別。結果顯示OLP組(含病灶處和其鄰近正常部位)之ZNF582甲基化程度與正常組相近；OLP組之ZNF582甲基化程度則低於上皮細胞變異和OSCC兩組。研究亦指出，在上皮細胞變異/OSCC組中，具有嚼食檳榔和抽菸之高風險生活習慣的患者，其ZNF582甲基化明顯高於沒有菸檳行為生活習慣的患者。而OLP患者其ZNF582甲基化程度則不受高風險生活習慣影響。
透過ZNF582甲基化程度證明OLP潛在惡性之可能性較低。
因此在臨床應用上Oral-M®可用以區分OLP與真正上皮細胞變異和口腔鱗狀細胞癌。
|
|
New publication shows that Oral-M® can distinguish oral lichen planus from other oral potentially malignant disorder with true dysplastic features and OSCC |
|
New Taipei City, January 28, 2022. iStat Biomedical Co., Ltd. (iStat Co.), shows data from multicenter trial were published in Oral Diseasesa.
This new study conducted in Chung Shan Medical University Hospital (CSMUH), Mackay Memorial Hospital (MMH) and Taipei Veterans General Hospital (TVGH), demonstrates that Oral-M® (ZNF582 methylation test) is able to distinguish oral lichen planus (OLP) from dysplasias and oral squamous cell carcinomas (OSCC).
This study has recruited 220 patients who were self-aware of oral abnormalities with 42 and 90 biopsy-confirmed dysplasias and OSCC patients, 43 clinically diagnosed OLP patients, and 45 normal controls. OLP lesions as well as adjacent normal showed comparable low ZNF582 methylation to normal control group, and lower than those of dysplasia and OSCC. Study also showed that dysplasia/OSCC patients with high-risk habits exhibited significantly higher ZNF582 methylation than those without high-risk habits. However, OLP patients were not affected by high-risk habits.
Based on ZNF582 methylation levels, OLP is unlikely to be potentially malignant. These clinical performance data support the use of Oral-M® for distinguishing OLP from true dysplastic features and OSCC during the clinical practice.
- Chiu, Y.-W., Su, Y.-F., Yang, C.-C., Liu, C.-J., Chen, Y.-J., Cheng, H.-C., Wu, C.-H., Chen, P.-Y., Lee, Y.-H., Chen, Y.-L., Chen, Y.-T., Peng, C.-Y., Lu, M.-Y., Yu, C.-H., Kao, S.-Y., Fwu, C.-W., & Huang, Y.-F. (2022). Is OLP potentially malignant? A clue from ZNF582 methylation. Oral Diseases, 00, 1–9. https://doi.org/10.1111/odi.14120
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518